Previous 10 | Next 10 |
MALVERN, Pa., May 25, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own a...
MALVERN, Pa., May 19, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, t...
2023-05-14 12:21:07 ET TELA Bio, Inc. (TELA) Q1 2023 Earnings Conference Call May 11, 2023 04.30 PM ET Company Participants Louisa Smith - Gilmartin Group Tony Koblish - President and CEO Roberto Cuca - COO and CFO Conference Call Participants Kyle Ro...
2023-05-11 16:13:08 ET TELA Bio press release ( NASDAQ: TELA ): Q1 GAAP EPS of -$0.63 misses by $0.04 . Revenue of $11.9M (+44.6% Y/Y) in-line. 2023 Financial Guidance We continue to expect full year 2023 revenue to range from $60 million to $65 million vs $61....
MALVERN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anat...
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient...
MALVERN, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own a...
MALVERN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the p...
2023-04-19 08:21:42 ET Allarity Therapeutics ( ALLR ) -33% . Femasys ( FEMY ) -25% anounces $3.9 million registered direct offering. Oblong ( OBLG ) -21% . Gamida Cell ( GMDA ) -16% on public offering . United Insurance Holdings ( ...
2023-04-19 05:00:09 ET Commercial-stage medical technology company, TELA ( NASDAQ: TELA ) announced underwritten public offering of 4.75M shares at a price to the public of $9.50 per share. Gross proceeds of $45.125M. Underwriters have a 30-day option to purchase up to...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 44 th Annual Growth Con...
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Mon...
2024-06-27 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...